These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1235 related articles for article (PubMed ID: 26860955)

  • 1. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Wong YC; Krainc D
    Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.
    Stojkovska I; Krainc D; Mazzulli JR
    Cell Tissue Res; 2018 Jul; 373(1):51-60. PubMed ID: 29064079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine.
    Blandini F; Cilia R; Cerri S; Pezzoli G; Schapira AHV; Mullin S; Lanciego JL
    Mov Disord; 2019 Jan; 34(1):9-21. PubMed ID: 30589955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocerebrosidase and its relevance to Parkinson disease.
    Do J; McKinney C; Sharma P; Sidransky E
    Mol Neurodegener; 2019 Aug; 14(1):36. PubMed ID: 31464647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.
    Sardi SP; Cheng SH; Shihabuddin LS
    Prog Neurobiol; 2015 Feb; 125():47-62. PubMed ID: 25573151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
    Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
    Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.
    Rockenstein E; Clarke J; Viel C; Panarello N; Treleaven CM; Kim C; Spencer B; Adame A; Park H; Dodge JC; Cheng SH; Shihabuddin LS; Masliah E; Sardi SP
    Hum Mol Genet; 2016 Jul; 25(13):2645-2660. PubMed ID: 27126635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
    Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
    Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
    Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
    Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ
    Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
    Kim MJ; Jeon S; Burbulla LF; Krainc D
    Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
    Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
    Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
    Henderson MX; Sedor S; McGeary I; Cornblath EJ; Peng C; Riddle DM; Li HL; Zhang B; Brown HJ; Olufemi MF; Bassett DS; Trojanowski JQ; Lee VMY
    Neuron; 2020 Mar; 105(5):822-836.e7. PubMed ID: 31899072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Glucocerebrosidase Dysfunction in Parkinson's Disease.
    Chatterjee D; Krainc D
    J Mol Biol; 2023 Jun; 435(12):168023. PubMed ID: 36828270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocerebrosidase dysfunction in neurodegenerative disease.
    Brooker SM; Krainc D
    Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.